Vaccine, Tetanus toxoid, tetanus toxoid adsorbed
Class : ( Vaccines, Antisera & Immunologicals )
P - Caution when used during pregnancy
L - Caution when used during lactation
Indication & Dosage
Parenteral
Active immunisation against tetanus
Adult: Primary immunisation (using tetanus toxoid adsorbed via deep IM Inj): 3 doses of 0.5 ml each; 2nd dose is given 4-8 wk after the 1st dose and the 3rd dose is given 6-12 mth after the 2nd dose. Booster dose (using tetanus toxoid via IM/SC or tetanus toxoid adsorbed via deep IM): 0.5 ml every 10 yr. Pregnant women who have not completed primary vaccination against tetanus: if insufficient time, 2 doses at least 4 wk apart (wait until second trimester to reduce risk to foetus), and 2nd dose at least 2 wk before delivery.
Child: =7 yr: Primary immunisation (using tetanus toxoid adsorbed via deep IM Inj): 3 doses of 0.5 ml each; 2nd dose is given 4-8 wk after the 1st dose and the 3rd dose is given 6-12 mth after the 2nd dose. Booster dose (using tetanus toxoid via IM/SC or tetanus toxoid adsorbed via deep IM): 0.5 ml every 10 yr.
Parenteral
Postexposure prophylaxis of tetanus
Adult: Emergency booster dose of 0.5 ml tetanus toxoid (IM/SC) or tetanus toxoid adsorbed (Deep IM Inj) to be given: if previously received <3 doses of a tetanus toxoid-containing preparation. Emergency dose is also needed if the wound is clean and minor and >10 yr have lapsed since primary immunisation or last booster dose of tetanus toxoid-containing preparation. For all other wounds, emergency dose is needed if >5 yr have lapsed since primary immunisation or the last booster dose of tetanus toxoid-containing preparation.
Special Precautions
Do not administer IV. Use subcutaneous route in bleeding disorders. Withhold vaccination in moderate or severe febrile illness. Pregnancy, lactation, history of Guillian-Barre syndrome.
Adverse Drug Reactions
Mild inj site reactions eg transient swelling, rash, fever, malaise, tiredness, nausea, vomiting, arthralgias, pruritus, dizziness.
Potentially Fatal: Anaphylactic reactions.
Drug Interactions
Decreased immunologic response with concurrent immunosuppressants. Neutralisation of tetanus immune globulin and tetanus toxoid adsorbed if not given at different sites using different syringes.
Storage
Parenteral: Store at 2–8°C. Do not freeze.
Mechanism of Action
Tetanus toxoid and tetanus toxoid adsorbed induces active immunity to the tetanus antigen by stimulating the immune system to produce specific antitoxin. They are not indicated for the treatment of active tetanus infection.
Pharmacological Classification
Tetanus toxoid; Belongs to the class of tetanus bacterial vaccines. Used in vaccination.
Brands : ANTI-TET (ATS) inj BETT inj , SHAN-TT amp , TETANUS ANTITOXIN inj , TETANUS TOXOID (ADSORBED) inj TETANUS TOXOID ADSORBED amp TETANUS TOXOID-ADSORBED inj TETANUS-TOXOID amp , TETANUS-TOXOID vial , TETIG amp , TETIG INJ amp , TET-VAC amp
Class : ( Vaccines, Antisera & Immunologicals )
P - Caution when used during pregnancy
L - Caution when used during lactation
Indication & Dosage
Parenteral
Active immunisation against tetanus
Adult: Primary immunisation (using tetanus toxoid adsorbed via deep IM Inj): 3 doses of 0.5 ml each; 2nd dose is given 4-8 wk after the 1st dose and the 3rd dose is given 6-12 mth after the 2nd dose. Booster dose (using tetanus toxoid via IM/SC or tetanus toxoid adsorbed via deep IM): 0.5 ml every 10 yr. Pregnant women who have not completed primary vaccination against tetanus: if insufficient time, 2 doses at least 4 wk apart (wait until second trimester to reduce risk to foetus), and 2nd dose at least 2 wk before delivery.
Child: =7 yr: Primary immunisation (using tetanus toxoid adsorbed via deep IM Inj): 3 doses of 0.5 ml each; 2nd dose is given 4-8 wk after the 1st dose and the 3rd dose is given 6-12 mth after the 2nd dose. Booster dose (using tetanus toxoid via IM/SC or tetanus toxoid adsorbed via deep IM): 0.5 ml every 10 yr.
Parenteral
Postexposure prophylaxis of tetanus
Adult: Emergency booster dose of 0.5 ml tetanus toxoid (IM/SC) or tetanus toxoid adsorbed (Deep IM Inj) to be given: if previously received <3 doses of a tetanus toxoid-containing preparation. Emergency dose is also needed if the wound is clean and minor and >10 yr have lapsed since primary immunisation or last booster dose of tetanus toxoid-containing preparation. For all other wounds, emergency dose is needed if >5 yr have lapsed since primary immunisation or the last booster dose of tetanus toxoid-containing preparation.
Special Precautions
Do not administer IV. Use subcutaneous route in bleeding disorders. Withhold vaccination in moderate or severe febrile illness. Pregnancy, lactation, history of Guillian-Barre syndrome.
Adverse Drug Reactions
Mild inj site reactions eg transient swelling, rash, fever, malaise, tiredness, nausea, vomiting, arthralgias, pruritus, dizziness.
Potentially Fatal: Anaphylactic reactions.
Drug Interactions
Decreased immunologic response with concurrent immunosuppressants. Neutralisation of tetanus immune globulin and tetanus toxoid adsorbed if not given at different sites using different syringes.
Storage
Parenteral: Store at 2–8°C. Do not freeze.
Mechanism of Action
Tetanus toxoid and tetanus toxoid adsorbed induces active immunity to the tetanus antigen by stimulating the immune system to produce specific antitoxin. They are not indicated for the treatment of active tetanus infection.
Pharmacological Classification
Tetanus toxoid; Belongs to the class of tetanus bacterial vaccines. Used in vaccination.
Brands : ANTI-TET (ATS) inj BETT inj , SHAN-TT amp , TETANUS ANTITOXIN inj , TETANUS TOXOID (ADSORBED) inj TETANUS TOXOID ADSORBED amp TETANUS TOXOID-ADSORBED inj TETANUS-TOXOID amp , TETANUS-TOXOID vial , TETIG amp , TETIG INJ amp , TET-VAC amp